METLIFE INC — Director's Dealing 2019

Jun 17, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: METLIFE INC (MET)
CIK: 0001099219
Period of Report: 2019-06-13

Reporting Person: KILTS JAMES M (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-06-13	Common Stock	A	480	$48.51	Acquired	74379	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-06-13	Deferred Share Equivalents	$	A	105	Acquired		Common Stock (105.0)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	236	Indirect

Footnotes

F1: Represents imputed reinvestment of dividends on Deferred Shares in the Reporting Person's deferral account pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred Shares represent shares of MetLife, Inc. common stock that have become payable, but that remain unpaid because payment has been deferred.

F2: The Reporting Person disclaims beneficial ownership of 76.44% of shares held by JMK Investments 2, LP, representing limited partnership interests in trusts for the benefit of each of his children.

F3: Each Deferred Share Equivalent is the economic value of one share of MetLife, Inc. common stock. Deferred Share Equivalents were acquired pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors, whereby Directors may elect to defer receipt of cash retainer fees for a specified period of time into a fund that tracks MetLife, Inc. common stock. Deferred Share Equivalents are settled in cash. Directors may transfer deferred cash retainer fees out of the fund that tracks MetLife, Inc. common stock and into other simulated investments.

F4: Represents imputed reinvestment of dividends on Deferred Share Equivalents.

F5: Deferred Share Equivalents were previously referred to as "Common Stock Equivalent Units." Beginning with this report, the Reporting Person will report the total of all the person's Deferred Share Equivalents in Table II Box 9.